55 related articles for article (PubMed ID: 19281372)
1. In vivo toxicity, pharmacokinetic features, and immunogenicity of B43(Anti-CD19)-genistein immunoconjugate in mice and non-human primates.
Myers DE; Uckun FM
J Med Food; 1999; 2(3-4):173-5. PubMed ID: 19281372
[No Abstract] [Full Text] [Related]
2. In vivo toxicity and pharmacokinetic features of B43 (anti-CD19)-genistein immunoconjugate in nonhuman primates.
Messinger Y; Yanishevski Y; Ek O; Zeren T; Waurzyniak B; Gunther R; Chelstrom L; Chandan-Langlie M; Schneider E; Myers DE; Evans W; Uckun FM
Clin Cancer Res; 1998 Jan; 4(1):165-70. PubMed ID: 9516966
[TBL] [Abstract][Full Text] [Related]
3. In vivo toxicity and pharmacokinetic features of B43(Anti-CD19)-Genistein immunoconjugate.
Ek O; Yanishevski Y; Zeren T; Waurzyniak B; Gunther R; Chelstrom L; Chandan-Langlie M; Schneider E; Myers DE; Evans W; Uckun FM
Leuk Lymphoma; 1998 Jul; 30(3-4):389-94. PubMed ID: 9713969
[TBL] [Abstract][Full Text] [Related]
4. Large scale manufacturing of B43(anti-CD19)-genistein for clinical trials in leukemia and lymphoma.
Myers DE; Sicheneder A; Clementson D; Dvorak N; Venkatachalam T; Sev AR; Chandan-Langlie M; Uckun FM
Leuk Lymphoma; 1998 Apr; 29(3-4):329-38. PubMed ID: 9684930
[TBL] [Abstract][Full Text] [Related]
5. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor.
Uckun FM; Messinger Y; Chen CL; O'Neill K; Myers DE; Goldman F; Hurvitz C; Casper JT; Levine A
Clin Cancer Res; 1999 Dec; 5(12):3906-13. PubMed ID: 10632319
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys.
Uckun FM; Yanishevski Y; Tumer N; Waurzyniak B; Messinger Y; Chelstrom LM; Lisowski EA; Ek O; Zeren T; Wendorf H; Langlie MC; Irvin JD; Myers DE; Fuller GB; Evans W; Gunther R
Clin Cancer Res; 1997 Mar; 3(3):325-37. PubMed ID: 9815689
[TBL] [Abstract][Full Text] [Related]
7. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM
Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881
[TBL] [Abstract][Full Text] [Related]
8. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo.
Noujaim AA; Schultes BC; Baum RP; Madiyalakan R
Cancer Biother Radiopharm; 2001 Jun; 16(3):187-203. PubMed ID: 11471484
[TBL] [Abstract][Full Text] [Related]
9. Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinoside.
Messinger Y; Yanishevski Y; Avramis VI; Ek O; Chelstrom LM; Gunther R; Myers DE; Irvin JD; Evans W; Uckun FM
Clin Cancer Res; 1996 Sep; 2(9):1533-42. PubMed ID: 9816330
[TBL] [Abstract][Full Text] [Related]
10. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.
Scott CF; Goldmacher VS; Lambert JM; Jackson JV; McIntyre GD
J Natl Cancer Inst; 1987 Nov; 79(5):1163-72. PubMed ID: 3500356
[TBL] [Abstract][Full Text] [Related]
11. Establishment of a human t(4;11) leukemia in severe combined immunodeficient mice and successful treatment using anti-CD19 (B43)-pokeweed antiviral protein immunotoxin.
Jansen B; Uckun FM; Jaszcz WB; Kersey JH
Cancer Res; 1992 Jan; 52(2):406-12. PubMed ID: 1370213
[TBL] [Abstract][Full Text] [Related]
12. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.
Blanc V; Bousseau A; Caron A; Carrez C; Lutz RJ; Lambert JM
Clin Cancer Res; 2011 Oct; 17(20):6448-58. PubMed ID: 22003072
[TBL] [Abstract][Full Text] [Related]
13. Generation and characterization of an anti-CD19 single-chain Fv immunotoxin composed of C-terminal disulfide-linked dgRTA.
Wang D; Li Q; Hudson W; Berven E; Uckun F; Kersey JH
Bioconjug Chem; 1997; 8(6):878-84. PubMed ID: 9404661
[TBL] [Abstract][Full Text] [Related]
14. Intravenous injection of an immunoconjugate (anti-PSA-IgG conjugated to 5-fluoro-2'-deoxyuridine) selectively inhibits cell proliferation and induces cell death in human prostate cancer cell tumors grown in nude mice.
Sinha AA; Quast BJ; Reddy PK; Elson MK; Wilson MJ
Anticancer Res; 1999; 19(2A):893-902. PubMed ID: 10368631
[TBL] [Abstract][Full Text] [Related]
15. Eradication of CD19+ leukemia by targeted calicheamicin θ.
Bernt KM; Prokop A; Huebener N; Gaedicke G; Wrasidlo W; Lode HN
Bioconjug Chem; 2009 Aug; 20(8):1587-94. PubMed ID: 19572629
[TBL] [Abstract][Full Text] [Related]
16. Rational design of an immunoconjugate for selective knock-down of leukemia-specific E2A-PBX1 fusion gene expression in human Pre-B leukemia.
Uckun FM; Qazi S; Dibirdik I; Myers DE
Integr Biol (Camb); 2013 Jan; 5(1):122-32. PubMed ID: 22990208
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
Allen TM; Mumbengegwi DR; Charrois GJ
Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
[TBL] [Abstract][Full Text] [Related]
18. Engagement of the CD19 receptor on human B-lineage leukemia cells activates LCK tyrosine kinase and facilitates radiation-induced apoptosis.
Waddick KG; Chae HP; Tuel-Ahlgren L; Jarvis LJ; Dibirdik I; Myers DE; Uckun FM
Radiat Res; 1993 Dec; 136(3):313-9. PubMed ID: 7506428
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of an anti-CD7-ricin A chain immunoconjugate in a novel murine model of human T-cell leukemia.
Fishwild DM; Aberle S; Bernhard SL; Kung AH
Cancer Res; 1992 Jun; 52(11):3056-62. PubMed ID: 1375534
[TBL] [Abstract][Full Text] [Related]
20. Targeting colon cancer cells with genistein-17.1A immunoconjugate.
Gentile MS; Vasu C; Green A; Murillo G; Das Gupta TK; Constantinou AI; Prabhakar BS; Salti GI
Int J Oncol; 2003 May; 22(5):955-9. PubMed ID: 12684659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
